Nitric Oxide Releasing Coronary Stent: A New Approach Using Layer-by-Layer Coating and Liposomal Encapsulation.

The sustained or controlled release of nitric oxide (NO) can be the most promising approach for the suppression or prevention of restenosis and thrombosis caused by stent implantation. The aim of this study is to investigate the feasibility in the potential use of layer-by-layer (LBL) coating with a NO donor-containing liposomes to control the release rate of NO from a metallic stent. Microscopic observation and surface characterizations of LBL-modified stents demonstrate successful LBL coating with liposomes on a stent. Release profiles of NO show that the release rate is sustained up to 5 d. In vitro cell study demonstrates that NO release significantly enhances endothelial cell proliferation, whereas it markedly inhibits smooth muscle cell proliferation. Finally, in vivo study conducted with a porcine coronary injury model proves the therapeutic efficacy of the NO-releasing stents coated by liposomal LBL technique, supported by improved results in luminal healing, inflammation, and neointimal thickening except thrombo-resistant effect. As a result, all these results demonstrate that highly optimized release rate and therapeutic dose of NO can be achieved by LBL coating and liposomal encapsulation, followed by significantly efficacious outcome in vivo.

[1]  Y. Weng,et al.  Immobilization of selenocystamine on TiO2 surfaces for in situ catalytic generation of nitric oxide and potential application in intravascular stents. , 2011, Biomaterials.

[2]  P. Hammond.  Thin films: Particles release. , 2010, Nature materials.

[3]  Yu-Chao Wang,et al.  Heat-activated sustaining nitric oxide release from zwitterionic diazeniumdiolate loaded in thermo-sensitive liposomes. , 2010, Nitric oxide : biology and chemistry.

[4]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[5]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[6]  Chi H. Lee.  Treatment of blood flow abnormality using mucosal delivery of nitric oxide , 2011, Drug Delivery and Translational Research.

[7]  Y. Weng,et al.  Nitric oxide producing coating mimicking endothelium function for multifunctional vascular stents. , 2015, Biomaterials.

[8]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[9]  S. Antimisiaris,et al.  Liposome-coated metal stents: an in vitro evaluation of controlled-release modality in the ureter. , 2000, Journal of endourology.

[10]  R. Virmani,et al.  A review of current devices and a look at new technology: drug-eluting stents , 2009, Expert review of medical devices.

[11]  A. Seifalian,et al.  Nitric oxide-eluting nanocomposite for cardiovascular implants , 2014, Journal of Materials Science: Materials in Medicine.

[12]  S. Windecker,et al.  Late Coronary Stent Thrombosis , 2007, Circulation.

[13]  F. Barry,et al.  Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model , 2011, Gene Therapy.

[14]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.

[15]  J. Zweier,et al.  4-Aryl-1,3,2-oxathiazolylium-5-olates as pH-controlled NO-donors: the next generation of S-nitrosothiols. , 2007, Journal of the American Chemical Society.

[16]  T. Arnebrant,et al.  Influence of pH on the build-up of poly-L-lysine/heparin multilayers. , 2012, Journal of colloid and interface science.

[17]  M. Tirrell,et al.  Liposome encapsulation of a photochemical NO precursor for controlled nitric oxide release and simultaneous fluorescence imaging. , 2012, Molecular pharmaceutics.

[18]  Patrick W Serruys,et al.  Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.

[19]  A. Wan,et al.  Preparation and characterization of diazeniumdiolate releasing ethylcellulose films , 2009, Journal of materials science. Materials in medicine.

[20]  G. Mani,et al.  A stent for co-delivering paclitaxel and nitric oxide from abluminal and luminal surfaces: Preparation, surface characterization, and in vitro drug release studies , 2013 .

[21]  Hua Xu,et al.  2-Hydroxy-5-nitrobenzyl as a diazeniumdiolate protecting group: application in NO-releasing polymers with enhanced biocompatibility. , 2008, Organic letters.

[22]  V. Barron,et al.  Liposomal surface coatings of metal stents for efficient non-viral gene delivery to the injured vasculature. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[23]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[24]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[25]  Qiufen Tu,et al.  Constructing Biomimic Catalytic Coating with Controlled Nitric Oxide Release Properties by Immobilizing 3,3-Diselenodipropionic Acid on Plasma Polymerized Allylamine Film , 2014 .

[26]  Gregory Gregoriadis,et al.  Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes , 1984, Bio/Technology.

[27]  W. Durante,et al.  ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION , 2007, Clinical and experimental pharmacology & physiology.

[28]  D. Karnabatidis,et al.  Dexamethasone incorporating liposomes: an in vitro study of their applicability as a slow releasing delivery system of dexamethasone from covered metallic stents. , 2002, Biomaterials.

[29]  Mark E Meyerhoff,et al.  Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. , 2005, Biomaterials.

[30]  Benjamin Thierry,et al.  Bioactive coatings of endovascular stents based on polyelectrolyte multilayers. , 2003, Biomacromolecules.

[31]  L. Keefer.  Fifty Years of Diazeniumdiolate Research. From Laboratory Curiosity to Broad-Spectrum Biomedical Advances , 2011, ACS chemical biology.

[32]  S. Windecker,et al.  Drug-eluting stent thrombosis. , 2009, Minerva cardioangiologica.

[33]  Achala de Mel,et al.  Nitric oxide donors for cardiovascular implant applications. , 2013, Small.

[34]  S. Antimisiaris,et al.  Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility. , 2006, Biomaterials.

[35]  A. de Mel,et al.  Inception to actualization: next generation coronary stent coatings incorporating nanotechnology. , 2013, Journal of biotechnology.

[36]  A. Khoury,et al.  A liposomal hydrogel for the prevention of bacterial adhesion to catheters. , 1998, Biomaterials.

[37]  P. Tsao,et al.  Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. , 2004, Cardiovascular research.

[38]  G. Gilardi,et al.  Layer-by-Layer Assembly of Supported Lipid Bilayer Poly-L-Lysine Multilayers. , 2016, Biomacromolecules.

[39]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[40]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.